The results presented at the 2021 European Society of Photobiology conference demonstrate that Ondine’s broad-spectrum nasal photodisinfection technology eliminates COVID at the genomic and advanced protein level.
Vancouver, Canada, September 18, 2021 (GLOBE NEWSWIRE) –
Nasal decolonization is recommended by the WHO and the CDC to reduce nosocomial infections (HAIs),  that have been exacerbated by COVID. 
HAIs in US hospitals cause up to $ 45 billion in additional direct medical costs each year. 
Ondine Biomedical, specialist in medical devices based on photodesinfection, presented in vitro and in vivo results which demonstrated the elimination of the SARS-CoV-2 genome after less than a few minutes of photodesinfection treatment at the recent conference of the European Society of Photobiology in Austria.
Ondine’s photodesinfection technology has also been shown to destroy spike protein and receptor binding domains of various major viral variants, including the highly infectious Delta variant from India. These findings underscored in vivo results provided by industrial users, where COVID-19 infection rates in treated workers decreased significantly compared to untreated workers.
Dr Nicolas Loebel, President and Chief Technology Officer, told the meeting: “The nose is a major reservoir of SARS-CoV-2. As the majority of COVID-19 transmissions come from asymptomatic carriers, Ondine’s approach to this highly infectious virus is to focus on reducing transmission by decolonizing patients’ noses of all pathogens. This application is a natural extension of Ondine’s Steriwave ™ nasal photodisinfection technology that has been deployed over the past decade in Canadian hospitals and clinics to reduce healthcare associated infections.
“When a colonized person coughs or sneezes, pathogens can be aerosolized in the upper respiratory tract and passed on to other patients, colleagues and healthcare professionals. This can happen whether or not the patient is vaccinated or has symptoms of COVID-19. We believe that a powerful and rapid decolonization method like Steriwave could become a key part of controlling viral transmission alongside masks, vaccines and antibody therapies.
“The majority of current pathogen therapies fail at some point due to the development of resistance,” Loebel continued. “With the continued emergence of virulent SARS-CoV-2 mutations that can spread across the globe within months, we intend to advance our photodesinfection-based protocols and clinical efforts as quickly as possible to provide patients and healthcare professionals with a new tool in the fight against these and other types of emerging respiratory pathogens.
The nose has been identified as a fertile ground and an ideal reservoir for many pathogens, including MRSA, Candida auris and SARS-Cov-2. Steriwave has been shown to quickly and painlessly eradicate bacteria, viruses and fungi from the nose. The patented platform technology involves a two-step process: applying a liquid photosensitizer to each nostril, followed by illumination with non-thermal laser light for less than five minutes. This combination destroys pathogens via oxidative stress. The main benefits of this painless nasal decolonization approach include instant broad spectrum action; easy integration into hospital and clinic workflows; high compliance rates; and the lack of resistance generation by the targeted pathogens.
Steriwave has received the CE mark and is approved in Canada and several other countries for the decolonization of intranasal pathogens. In the United States, Steriwave is currently in clinical trials for regulatory approval. Steriwave has been used in Canadian hospitals for the past decade for nasal decolonization to reduce the incidence of nosocomial infections.
Steriwave photodisinfection therapy retains its efficacy despite its reuse; is easy and painless to administer, takes only a few minutes to kill bacteria, viruses and fungi; does not require adherence or complex multi-step treatment regimens; and can be applied by any healthcare professional. This is especially important during the current pandemic, as research has shown that pathogenic cofactors worsen the results of COVID-19 by altering the skin’s natural immunity and host defenses. 
Ondine’s Steriwave photodesinfection technology offers an alternative in the fight against drug-resistant infections. Also known as Antimicrobial Photodynamic Disinfection Therapy (aPDT), this light-activated antimicrobial kills a broad spectrum of drug-resistant bacteria, viruses and fungi, including those in biofilms, while dramatically reducing local inflammation. The CE marked Steriwave technology involves applying a photosensitive agent to each nostril, followed by illuminating the area with non-thermal laser light for less than five minutes. This causes an oxidative explosion which destroys pathogens. When the light is off, the reaction ceases.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian medical device company led by Founder and CEO, Carolyn Cross. Ondine has developed a patented and painless photodisinfection technology platform used in treatment and prevention therapies for a broad spectrum of pathogens – bacterial, viral and fungal – including multidrug resistant strains. In addition to Steriwave for nasal disinfection, other applications of the photodesinfection platform are under development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and, more recently, the development of topical antiviral therapy for the upper respiratory tract to reduce titer and transmission of SARS-CoV-2.
 Prevention of surgical site infections: Key facts about the decolonization of nasal carriers of Staphylococcus aureus (WHO).
Global guidelines for the prevention of surgical site infections (WHO 2018).
New WHO recommendations on preoperative measures for the prevention of surgical site infections.
Strategies for preventing Staphylococcus aureus blood infections in hospital in acute care (CDC) facilities.
CONTACT: Angelika Vance Ondine Biomedical Inc. 6048382702 [email protected] Simon Vane Percy / Amanda Bernard (T) +44 (0)7710 005 910 / + 44 (0)77763 73269 [email protected] [email protected]